Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus
Interventions:   Drug: thyroxine;   Drug: Placebo;   Other: A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)
Sponsor:   Attikon Hospital
Completed - verified July 2015

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified May 2015

Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease

Conditions:   Alzheimer´s Disease;   Diabetes Mellitus Type 2
Intervention:   Other: There is a retrospectiv observational study. No intervention
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Recruiting - verified July 2015

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified July 2015

Diabetes Risk Reduction Through Eat, Walk, Sleep and Medication Therapy Management for Depressed Cambodians

Conditions:   Diabetes;   Depression
Interventions:   Behavioral: Enhanced standard care;   Behavioral: Lifestyle;   Behavioral: Lifestyle Plus Medication Therapy Management
Sponsors:   University of Connecticut Health Center;   Khmer Health Advocates;   University of Connecticut;   Penn State University
Not yet recruiting - verified July 2015

The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Liraglutide;   Drug: metformin
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Recruiting - verified July 2015

Glucose Response, Excursions And Treatment (GREAT) Study

Condition:   Type 2 Diabetes
Interventions:   Drug: DPPIV inhibitor -;   Device: Continuous glucose monitoring system.
Sponsors:   Royal Devon and Exeter NHS Foundation Trust;   NIHR Exeter Clinical Research Facility
Recruiting - verified July 2015

Effect of Dapagliflozine on Systemic and Renal Endothelial Function

Conditions:   Endothelial Function;   Type 2 Diabetes
Interventions:   Drug: Metformin;   Drug: Dapagliflozin
Sponsor:   Seoul National University Hospital
Recruiting - verified July 2015

Mitigation of Type 2 Diabetes by Partial Ileal Bypass

Condition:   Type 2 Diabetes
Intervention:  
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   East Carolina University;   Harvard Medical School;   Weill Medical College of Cornell University
Not yet recruiting - verified July 2015

The Drug-drug Interaction of SHR3824 and SP2086

Condition:   Type 2 Diabetes
Intervention:   Drug: SHR3824, SP2086
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Recruiting - verified July 2015

Defining the Molecular and Physiological Mechanisms of Pancreatic Islet Cell Dysfunction Which Lead to Type 2 Diabetes

Condition:   Diabetes Mellitus
Intervention:   Other: Glucose-Potentiated Arginine-Induced Insulin Secretion
Sponsors:   NIHR Exeter Clinical Research Facility;   University of Exeter;   Royal Devon and Exeter NHS Foundation Trust;   University of Oxford;   Oxford University Hospitals NHS Trust
Recruiting - verified July 2015

Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients

Conditions:   Endothelial Function;   Type 2 Diabetes;   Gemigliptin;   Acarbose
Interventions:   Drug: Gemigliptin;   Drug: Acarbose
Sponsor:   Seoul National University Hospital
Recruiting - verified July 2015

Does Prolonged Fasting Break the Vicious Circle of Polycystic Ovarian Syndrome ? SYNDROME OF INSULIN RESISTANCE

Condition:   Polycystic Ovary Syndrome
Intervention:  
Sponsor:   Ain Shams University
Not yet recruiting - verified July 2015

Myocardial Regional Function by Dobutamine Stress Echocardiography in the Metabolic Syndrome and Type 2 Diabetes

Condition:   Diabetes-related Complications
Intervention:   Drug: dobutamine
Sponsor:   University of Avignon
Recruiting - verified July 2015

Impacts of Intermittent Fasting on Energy Balance and Associated Health Outcomes

Conditions:   Obesity;   Type 2 Diabetes
Interventions:   Device: Physical Activity Monitoring (Actiheart);   Other: Energy Intake Monitoring;   Other: Body Weight Monitoring;   Procedure: Intravenous Cannulation;   Procedure: Adipose Tissue Biopsy;   Drug: Lidocaine Hydrochloride;   Other: Post-Prandial Meal Tests;   Radiation: DEXA Scan;   Other: Actiheart Calibration;   Other: Daily Calorie Restriction;   Other: Intermittent Fasting with Weight Loss;   Other: Intermittent Fasting without Weight Loss
Sponsor:   University of Bath
Recruiting - verified July 2015

for Adipose Tissue DIabetes VAriants (fATDIVA)

Condition:   Diabetes Mellitus
Interventions:   Other: Oral Triglyceride Tolerance Test (OTTT);   Procedure: Abdominal fat biopsy (optional)
Sponsors:   NIHR Exeter Clinical Research Facility;   University of Exeter;   Royal Devon and Exeter NHS Foundation Trust
Recruiting - verified July 2015

Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting

Condition:   Healthy
Interventions:   Other: Fasting;   Drug: Saline;   Drug: Pegvisomant
Sponsor:   University of Aarhus
Recruiting - verified July 2015

Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)

Conditions:   Polycystic Ovary Syndrome;   Non-Alcoholic Fatty Liver Disease;   Metabolic Syndrome
Interventions:   Drug: Metformin;   Drug: Placebo
Sponsor:   Columbia University
Recruiting - verified July 2015

A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care

Conditions:   Pain;   Chronic Pain;   Mental Disorders;   Cardiovascular Diseases;   Diabetes Mellitus, Type 2;   Arthritis
Interventions:   Other: Unblinded to Genetic Testing Results;   Other: Blinded to Genetic Testing Results
Sponsor:   Proove Bioscience, Inc.
Recruiting - verified July 2015

The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor

Condition:   Diabetes Melltius, Type 2
Interventions:   Drug: Luseogliflozin;   Other: Meal containing different carbohydrate ratio and GI value
Sponsors:   Kansai Electric Power Hospital;   Medical Corporation Heishinkai OCROM Clinic
Active, not recruiting - verified June 2015

Online Support for Diabetes Self-Management

Condition:   Diabetes Mellitus Type 2
Intervention:   Behavioral: Online Support
Sponsors:   University of British Columbia;   University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting - verified July 2015

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptinin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Conditions:   Type 2 Diabetes Mellitus,;   Inadequate Glycaemic Control
Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Glimepiride;   Drug: Placebo for dapagliflozin;   Drug: Placebo for saxagliptin;   Drug: Placebo for glimepiride
Sponsor:   AstraZeneca
Not yet recruiting - verified July 2015

Neck Grasp as a Predictor of Sleep Apnea

Conditions:   Obstructive Sleep Apnea;   Type 2 Diabetes
Interventions:   Other: polysomnogram;   Other: home sleep test;   Other: Easy Sleep Apnea Predictor
Sponsor:   Bassett Healthcare
Recruiting - verified June 2015

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Recruiting - verified July 2015

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin 10 mg + linagliptin 5 mg;   Drug: empagliflozin 10 mg;   Drug: empagliflozin 25 mg + linagliptin 5 mg;   Drug: empagliflozin 25 mg;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2015

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Empagliflozin placebo + linagliptin placebo;   Drug: Empagliflozin + linagliptin low dose;   Drug: Linagliptin lacebo;   Drug: Empagliflozin + linagliptin high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2015

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified July 2015

Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes

Conditions:   Type 2 Diabetes;   Overweight;   Obesity;   Masked Hypertension
Interventions:   Drug: "Liraglutide" and "Mitiglinide";   Drug: "Metformin" and "Mitiglinide";   Drug: "Mitiglinide"
Sponsor:   Third Affiliated Hospital of Third Military Medical University
Active, not recruiting - verified July 2015

The Effects of Jerusalem Artichoke and Fermented Soybean Powder Mixture Supplementation on Glucose Control

Conditions:   Prediabetes;   Newly Diagnosed Type 2 Diabetes
Interventions:   Dietary Supplement: jerusalem artichoke and fermented soybeans powder mixture;   Dietary Supplement: placebo
Sponsor:   Yonsei University
Completed - verified July 2015

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: KD026;   Drug: Placebo;   Drug: Metformin
Sponsor:   Kadmon Corporation, LLC
Recruiting - verified July 2015

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Low Metformin;   Drug: Mid Metformin;   Drug: High Metformin;   Drug: Metformin
Sponsor:   NuSirt Biopharma
Active, not recruiting - verified July 2015

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Matching Placebo for Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified July 2015

Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic Patients

Conditions:   Microalbuminuria;   Microalbuminuria /Creatinine Ratios ACR
Interventions:   Drug: Saxagliptin;   Drug: glimepiride
Sponsor:   The Second Hospital of Nanjing Medical University
Enrolling by invitation - verified April 2015

Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: INSULIN GLARGINE (U300)
Sponsor:   Sanofi
Recruiting - verified July 2015

A Hepatitis B With Hepatic Steatosis Study

Conditions:   Hepatitis B, Chronic;   Hepatic Steatosis
Intervention:  
Sponsors:   Fatty Liver and Alcoholic Liver Disease Study Group, China;   Unimed Scientific Inc.
Not yet recruiting - verified July 2015

Fatty Liver Disease Collaborative Research in China

Conditions:   Fatty Liver;   Fatty Liver, Alcoholic;   Non-alcoholic Fatty Liver Disease
Intervention:  
Sponsors:   Fatty Liver and Alcoholic Liver Disease Study Group, China;   Unimed Scientific Inc.
Not yet recruiting - verified July 2015

A Observational Study to Evaluate Lipid-lowering Drug Its Effect on Parameters in Dyslipidemia of Type 2 Diabetes.

Condition:   Complex Dyslipidemia
Intervention:  
Sponsor:   Yooyoung Pharmaceutical Co.,Ltd.
Completed - verified July 2015

A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: DA-1229_01;   Drug: E+M
Sponsor:   Dong-A ST Co., Ltd.
Completed - verified July 2015

Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease

Conditions:   Retinal Neurodegeneration;   Alzheimer´s Disease;   Type 2 Diabetes
Intervention:  
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Recruiting - verified July 2015

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Teneligliptin;   Drug: Canagliflozin;   Drug: Placebo
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Recruiting - verified July 2015

The Drug-drug Interaction of SHR3824 and Metformin

Condition:   Type 2 Diabetes
Intervention:   Drug: SHR3824 metformin
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Completed - verified January 2015

Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Obesity
Interventions:   Procedure: Bariatric surgery involving Roux-en-Y gastric bypass;   Procedure: Bariatric surgery involving Laparoscopic adjustable gastric banding;   Procedure: Bariatric surgery involving Laparoscopic sleeve gastrectomy
Sponsors:   The Cleveland Clinic;   Medtronic - MITG;   Ethicon, Inc.
Enrolling by invitation - verified July 2015

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine U300 HOE901;   Drug: Insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified July 2015

Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Acarbose
Sponsor:   Zilin Sun
Recruiting - verified July 2015

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

Conditions:   Overweight;   Obesity
Interventions:   Device: Gelesis100;   Device: placebo
Sponsor:   Gelesis, Inc.
Recruiting - verified April 2015

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2963016;   Drug: LANTUS®;   Drug: Oral Antihyperglycemic Medication
Sponsors:   Eli Lilly and Company;   Boehringer Ingelheim
Recruiting - verified July 2015

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR342434;   Drug: insulin lispro;   Drug: insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified July 2015

Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Canagliflozin;   Drug: Liraglutide
Sponsors:   Ralph DeFronzo, MD;   Janssen Scientific Affairs, LLC
Recruiting - verified July 2015

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Sitagliptin;   Drug: Placebo matching with Saxagliptin;   Drug: Placebo matching with Dapagliflozin;   Drug: Placebo matching with Sitagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified February 2015

Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes

Condition:   Diabetes Mellitus
Interventions:   Device: Continuous Glucose Monitor;   Other: Continuous Subcutaneous insulin infusion
Sponsors:   DexCom, Inc.;   Jaeb Center for Health Research
Recruiting - verified July 2015

Exercise Training and Fitness in Severe Obesity

Condition:   Obesity
Interventions:   Other: Fatmax group;   Other: HIIT group
Sponsors:   Istituto Auxologico Italiano;   University of Lausanne
Completed - verified July 2015

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

Condition:   Insulin Sensitivity
Interventions:   Drug: Eritoran;   Other: D5W
Sponsor:   Nicolas Musi, MD
Recruiting - verified July 2015

Linagliptin as Add on to Basal Insulin in the Elderly

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2015

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: Exenatide;   Drug: Exenatide matching placebo
Sponsor:   AstraZeneca
Recruiting - verified July 2015

Phase 3 28 Week Study and 24 Week Extension to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Condition:   Diabetes Mellitus
Interventions:   Drug: Exantide with Dapagliflozin;   Drug: Exentide;   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified July 2015

Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Canagliflozin (TA-7284) +insulin;   Drug: Placebo+insulin
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Active, not recruiting - verified July 2015

TOFO Insulin Combination Trial

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: TOFOGLIFLOZIN CSG452;   Drug: insulin;   Drug: placebo
Sponsors:   Sanofi;   Kowa Company, Ltd.
Recruiting - verified July 2015

Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2015

Forxiga Tablets Specific Clinical Experience Investigation for Elderly

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified July 2015

Cocoa and Metabolic Health in Prediabetes

Condition:   Prediabetes
Intervention:   Other: Cocoa
Sponsors:   Virginia Polytechnic Institute and State University;   The Hershey Company
Recruiting - verified July 2015

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2015

Pyridorin in Diabetic Nephropathy

Conditions:   Diabetic Nephropathy;   Diabetic Kidney Disease
Interventions:   Drug: Pyridorin;   Drug: Placebo
Sponsors:   NephroGenex, Inc.;   Collaborative Study Group (CSG);   Medpace, Inc.
Recruiting - verified July 2015

A Study to Compare the Effect of Double Doses of Long-acting Insulin Therapies in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin Peglispro;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Completed - verified July 2015

Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Mitiglinide;   Drug: Acarbose
Sponsor:   Zhongda Hospital
Active, not recruiting - verified July 2015

Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin

Condition:   Type 2 Diabetes Mellitus
Intervention:   Dietary Supplement: SugarDown
Sponsor:   Boston Therapeutics
Completed - verified July 2015

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin medium dose;   Drug: empagliflozin high dose;   Drug: empagliflozin low dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2015

Metabolic Risk Following Gestational Diabetes Mellitus

Condition:   Gestational Diabetes
Intervention:   Other: Blood sampling and OGTT
Sponsor:   Hospices Civils de Lyon
Completed - verified July 2015

Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.

Condition:   Focus Type 2 Diabetes Related Chronic Kidney Disease
Intervention:   Behavioral: Exercise
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified July 2015

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2014

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2015

Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Teneli (Teneligliptin) /Teneli;   Drug: Placebo/Teneli (Teneligliptin);   Drug: Insulin
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Active, not recruiting - verified July 2015

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified July 2015

Egg Ingestion in Adults With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Dietary Supplement: Egg inclusion;   Dietary Supplement: Egg exclusion
Sponsors:   Griffin Hospital;   American Egg Board
Active, not recruiting - verified July 2015

Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease

Condition:   Ulcerative Colitis
Intervention:   Device: Capsule Endoscopy
Sponsor:   Medtronic - MITG
Active, not recruiting - verified May 2015

Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes

Conditions:   Diabetes;   Metabolic Syndrome;   Insulin Resistance
Intervention:   Drug: pegvisomant
Sponsors:   University of California, San Francisco;   San Francisco General Hospital
Active, not recruiting - verified July 2015

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified July 2015

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified July 2015

The Effects of Vitamin D Supplementation on Patients With Type 2 Diabetes and Vitamin D Deficiency

Conditions:   Diabetes Mellitus;   Vitamin D Deficiency
Intervention:   Dietary Supplement: vitamin D3
Sponsor:   HaEmek Medical Center, Israel
Recruiting - verified July 2015

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: lixisenatide AVE0010;   Drug: biguanide;   Drug: TZD;   Drug: alpha-GI;   Drug: glinide
Sponsor:   Sanofi
Active, not recruiting - verified July 2015

Specific Clinical Experience Investigation for Long-term Use of Bydureon

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2015

IMS® DIAREG Diabetes Registry

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: antidiabetic treatment (ATC A10B)
Sponsor:   IMS HEALTH GmbH & Co. OHG
Recruiting - verified July 2015

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2015

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: exenatide
Sponsor:   Novo Nordisk A/S
Completed - verified July 2015

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2015

Study Of Diabetic Nephropathy With Atrasentan

Condition:   Diabetic Nephropathy
Interventions:   Drug: Atrasentan;   Drug: Placebo
Sponsor:   AbbVie
Recruiting - verified July 2015

Genetics of Insulin and Incretins in Cystic Fibrosis

Condition:   Cystic Fibrosis
Interventions:   Genetic: Blood or Saliva Sample Collection;   Other: Glucose -potentiated arginine (GPA) stimulation tests
Sponsors:   Children's Hospital of Philadelphia;   University of Pennsylvania
Recruiting - verified July 2015

Osteoprosis in Type 2 Diabetic Patients- a Cohort Study

Conditions:   Type 2 Diabetes Mellitus;   Osteoporosis
Intervention:  
Sponsor:   National Taiwan University Hospital
Recruiting - verified July 2015

White Blood Cell Signaling and Defense Mechanisms in Patients With Diabetes Mellitus Type 2 and Periodontitis

Conditions:   Chronic Periodontitis;   Diabetes Mellitus, Type 2
Interventions:   Procedure: ADT+FD;   Procedure: FD
Sponsor:   Zentrum fuer Zahn-, Mund- und Kieferheilkunde
Active, not recruiting - verified July 2015

A Study of the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

Condition:   Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo to MK-3102;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified July 2015

Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2015

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Comparative Effectiveness of Glycemia-lowering Medications
Interventions:   Drug: Sulfonylurea (glimepiride);   Drug: DPP-4 inhibitor (sitagliptin);   Drug: GLP-1 receptor agonist (liraglutide);   Drug: Insulin (glargine)
Sponsors:   GRADE Study Group;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Heart, Lung, and Blood Institute (NHLBI);   Becton, Dickinson and Company;   Bristol-Myers Squibb;   Merck Sharp & Dohme Corp.;   Novo Nordisk A/S;   Hoffmann-La Roche;   Sanofi
Recruiting - verified July 2015

RISE Pediatric Medication Study

Conditions:   Prediabetes;   Type 2 Diabetes
Interventions:   Drug: Metformin;   Drug: Glargine
Sponsors:   RISE Study Group;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2015

RISE Adult Medication Study

Conditions:   Prediabetes;   Type 2 Diabetes
Interventions:   Drug: Metformin;   Drug: Liraglutide;   Drug: Glargine
Sponsors:   RISE Study Group;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2015

Better Diabetes Control, Quality - Educate to Achieve Compliance

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2015

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified July 2015

The Health Influences of Puberty (HIP) Study

Conditions:   Obesity;   Insulin Resistance;   Gonadal Dysfunction;   Type 2 Diabetes
Intervention:   Drug: Metformin
Sponsors:   University of Colorado, Denver;   American Diabetes Association;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Children's Hospital Colorado
Recruiting - verified July 2015

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Placebo matching with Dapagliflozin;   Drug: Saxagliptin;   Drug: Metformin immediate release (IR)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Completed - verified October 2014

Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin

Conditions:   Polycystic Ovary Syndrome;   Insulin Resistance
Interventions:   Drug: Metformin;   Drug: Clomiphene citrate
Sponsor:   OVO R & D
Withdrawn - verified July 2015

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: Dulaglutide;   Drug: Insulin glargine;   Drug: Insulin lispro
Sponsor:   Eli Lilly and Company
Recruiting - verified July 2015

Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea

Conditions:   Sleep Apnea, Obstructive;   Diabetes Mellitus
Interventions:   Device: Continuous positive airway pressure;   Device: Sham continuous positive airway pressure
Sponsors:   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center
Recruiting - verified July 2015

Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart 30;   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Completed - verified July 2015

Mobile Motivation for Health Promotion Among Adolescents

Condition:   Diabetes
Interventions:   Behavioral: Lifestyle text messages;   Behavioral: Attention Control Group
Sponsors:   BodiMojo, Inc.;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified July 2015

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Metformin Rescue;   Drug: Sitagliptin Rescue;   Biological: Insulin Rescue;   Biological: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2015

Mood and Insulin Resistance in Adolescents At-Risk for Diabetes

Conditions:   Depression;   Impaired Glucose Tolerance
Interventions:   Other: The Blues Program;   Other: Hey Durham
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institutes of Health Clinical Center (CC)
Active, not recruiting - verified March 2015

Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Paricalcitol;   Other: placebo
Sponsors:   Mario Negri Institute for Pharmacological Research;   Abbott
Completed - verified July 2015

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: BI1356 low dose;   Drug: BI1356 high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2015

The Effect of Gastric Bypass Surgery on Diabetes

Condition:   Type II Diabetes
Intervention:  
Sponsors:   University of Oulu;   Oulu University Hospital
Recruiting - verified July 2015

Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations

Conditions:   Diabetes;   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Enrolling by invitation - verified July 2015

Xanthohumol and Metabolic Syndrome

Condition:   Metabolic Syndrome
Intervention:   Dietary Supplement: Xanthohumol
Sponsors:   Oregon State University;   Oregon Health and Science University;   National Center for Complementary and Integrative Health (NCCIH)
Completed - verified July 2015

Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Active  titration algorithm;   Behavioral: Usual titration algorithm
Sponsor:   Mackay Memorial Hospital
Recruiting - verified July 2015

Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sulphonylurea;   Drug: Metformn
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone

Condition:   Infant, Small for Gestational Age
Intervention:  
Sponsors:   Merck KGaA;   Merck, S.L., Spain
Active, not recruiting - verified July 2015

Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

Condition:   Type 2 Diabetes
Interventions:   Drug: Co-administration of 50 mg sitagliptin and 500 mg metformin;   Drug: sitagliptin/metformin 50 mg/500 mg tablet;   Drug: Co-administration of 50 mg sitagliptin and 850 mg metformin;   Drug: sitagliptin/metformin 50 mg/850 mg tablet
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin phosphate;   Drug: Comparator: placebo to pioglitazone;   Drug: Comparator: placebo to Sitagliptin;   Drug: Comparator: pioglitazone;   Drug: Glimepiride or gliclazide;   Drug: Metformin;   Drug: Pioglitazone rescue therapy
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)

Conditions:   Nonalcoholic Steatohepatitis;   Nonalcoholic Fatty Liver Disease;   Type 2 Diabetes Mellitus
Interventions:   Drug: Pioglitazone;   Drug: Placebo;   Drug: Pioglitazone;   Drug: Placebo
Sponsors:   University of Florida;   The University of Texas at San Antonio
Completed - verified July 2015

Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Comparator: Placebo;   Drug: Pioglitazone;   Drug: Metformin;   Drug: Glipizide
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

Changing Lifestyles for Better Health

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Intensive Lifestyle Intervention
Sponsors:   Yale University;   Donaghue Medical Research Foundation
Completed - verified July 2015

MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)

Condition:   Diabetes Mellitus, Non-Insulin-Dependent
Interventions:   Drug: Comparator: Placebo;   Drug: Sitagliptin;   Drug: Voglibose
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-0941;   Drug: Placebo;   Drug: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Comparator: Sitagliptin phosphate;   Drug: Comparator: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

Training Effects on Skeletal Muscle Fatty Acid Metabolism

Condition:   Healthy Volunteers
Interventions:   Drug: 20% lipid infusion;   Drug: glycerol
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Completed - verified July 2015

Duodenal Exclusion for the Treatment of Type 2 Diabetes

Condition:   Diabetes
Intervention:   Procedure: Duodenal Exclusion
Sponsor:   Medtronic - MITG
Withdrawn - verified July 2015

Family Investigation of Nephropathy and Diabetes (F.I.N.D.)

Conditions:   Diabetic Nephropathy;   Diabetes Mellitus;   Diabetic Kidney Disease;   Albuminuria
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2015

Get CardioSmart

You're Invited